$69.32
Today
as of Jul 22, 16:52 ET
Last 30 days
Recent Press Releases & News
Cantor Fitzgerald Initiates Nektar Therapeutics at Buy With $153 Price Target
Nektar Initiates Two Registrational Trials in Phase 3 Program Evaluating Atopic Dermatitis Treatment
Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis
Overview
52-week range
$7.99
$109
61% of range
Avg surprise (last 3)
-7.0%
Avg reaction (last 2)
-0.2%
50% positive
Latest IV / EM
63%
EM ±14.4% · $70 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-1.82 | $-1.74 | -4.6% | -727.3% | -2.0% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-1.87 | — | — | — | — | financials |
| Thu Aug 7, 2025 | Jun/2025 | $-2.95 | $-3.13 | +5.8% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $-0.22 | $-0.18 | -22.2% | — | +1.6% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-2.66 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-3.76 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.19 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.24 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.27 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Thu Aug 6, 2026 | Jun/2026 | OTHER | -$1.94 | -$2.78 | +30.2% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | $0 | $0 | $0 | — | $4M | $10M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-39M | — | $-32M | $-36M | $-45M | — | $-34M | $-50M |
| Net income | $-45M | — | $-36M | $-42M | $-51M | — | $-37M | $-52M |
| EPS (diluted) | $-1.82 | — | $-1.87 | $-2.95 | $-3.62 | — | $-2.66 | $-3.76 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $150M | $15M | $41M | $43M | $39M | $44M | $30M | $28M |
| Inventory | — | — | — | — | — | — | $0 | $14M |
| Total current assets | $589M | $266M | $281M | $187M | $230M | $261M | $286M | $295M |
| Total assets | $763M | $280M | $301M | $208M | $256M | $304M | $308M | $343M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $187M | $191M | $216M | $232M | $243M | $243M | $259M | $264M |
| Total equity | $576M | $90M | $85M | $-24M | $14M | $61M | $49M | $80M |